中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03681 中国抗体-B

已收盘 04-08 15:59:52

1.720

-0.040

-2.27%

最高1.890	最低1.710	成交量580.86万
今开1.770	昨收1.760	日振幅10.23%
总市值23.86亿	流通市值23.86亿	总股本13.87亿
成交额1,045万	换手率0.42%	流通股本13.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03681","market":"HK","secType":"STK","nameCN":"中国抗体-B","latestPrice":1.72,"timestamp":1775635192061,"preClose":1.76,"halted":0,"volume":5808600,"delay":0,"changeRate":-0.02272727272727275,"floatShares":1387000000,"shares":1387000000,"eps":-0.09815712628264377,"marketStatus":"已收盘","change":-0.04,"latestTime":"04-08 15:59:52","open":1.77,"high":1.89,"low":1.71,"amount":10449707,"amplitude":0.102273,"askPrice":1.73,"askSize":10500,"bidPrice":1.72,"bidSize":30000,"shortable":0,"etf":0,"ttmEps":-0.09638096282487114,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775698200000},"marketStatusCode":5,"adr":0,"listingDate":1573488000000,"exchange":"SEHK","adjPreClose":1.76,"openAndCloseTimeList":[[1775611800000,1775620800000],[1775624400000,1775635200000]],"volumeRatio":1.260957,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03681","defaultTab":"news","newsList":[{"id":"2624500126","title":"海南海药拟减持中国抗体不超5%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500126","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624500126?lang=zh_cn&edition=full","pubTime":"2026-04-03 20:57","pubTimestamp":1775221020,"startTime":"0","endTime":"0","summary":"4月3日，海南海药（000566）发布公告，公司拟通过集中竞价交易及大宗交易的方式减持中国抗体（03681）股份数量不超过6800万股，不超过公司总股本的5%。截至公告披露日前一交易日，公司持有中国抗体1.59亿股股票资产的市值约为2.8亿港元，此次交易旨在优化公司资产结构，提高资产流动性及使用效率。2025年前三季度，海南海药实现收入6.40亿元，归母净利润-2.42亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695191451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0146","BK0070","BK1161","BK0239","000566","BK1574","BK0060","03681","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591113","title":"中国抗体-B(03681)：SM17治疗特应性皮炎中国2期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591113","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624591113?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:49","pubTimestamp":1775036988,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 发布公告，于2026年3月31日，SM17治疗特应性皮炎的2期临床试验已在中国成功完成首例患者给药。于2025年4月7日，本公司公布SM17在中国针对中重度特应性皮炎患者进行的1b期研究取得积极的顶线结果。该等结果显示SM17作为潜在首个兼具缓解瘙痒及皮肤修复双重疗效的特应性皮炎生物制剂的竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623003403","title":"中国抗体-B(03681)：陈海刚辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2623003403","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623003403?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:03","pubTimestamp":1774951429,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，陈海刚博士(陈博士)已提呈辞任非执行董事，自2026年3月31日起生效，以便投放更多时间于个人事务;及董汛先生(董先生)已提呈辞任非执行董事，自2026年4月1日起生效，乃由于其其他个人工作及业务承担。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622243000","title":"中国抗体-B(03681)：SM17在中国进行的给药途径转换1期桥接研究取得良好顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622243000","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622243000?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:57","pubTimestamp":1774432620,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 发布公告，本公司董事会欣然宣布SM17在中国进行的给药途径转换1期桥接研究取得良好顶线结果。临床报告于2024年第一季度获得，其显示出SM17 具有良好的安全性，并未报告任何与药物相关的严重不良反应。本公司2025年4月7日公布了在中国中重度AD患者中评估SM17初步疗效的概念验证性1b期临床试验的积极主要结果。于2026年2月，SM17用于治疗IBD患者的临床研究新药申请已获中国国家药品监督管理局批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国抗体-B(03681)：SM17在中国进行的给药途径转换1期桥接研究取得良好顶线结果","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061761","title":"中国抗体-B(03681)授出1157.48万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621061761?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:54","pubTimestamp":1774353294,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，于2026年3月24日，公司已根据2022年购股权计划向2名合资格人士授出1157.48万份购股权。购股权赋予承授人权利认购合共1157.48万股公司新股份，但须待承授人接纳后方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","03681","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120421645","title":"异动解读 | 中国抗体-B盘中大涨5.99%，年度亏损收窄及核心产品临床进展提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1120421645","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120421645?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:21","pubTimestamp":1774333279,"startTime":"0","endTime":"0","summary":"中国抗体-B今日盘中股价大幅上涨5.99%，引起了市场投资者的密切关注。消息面上，公司此前发布了截至2025年12月31日止年度的业绩公告。公告显示，公司年内亏损由2024年度的1.85亿元大幅减少8010万元至约1.05亿元，亏损收窄主要由于公司专注于SM17的1b期临床、转型桥接研究及筹备2期临床试验，其成本低于此前的大规模临床研究。此外，公司的财务状况显著改善，截至2025年底，可动用的资金总额为3.52亿元，较2024年同期的1.41亿元大幅增加。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770297","title":"中国抗体-B(03681)2025年亏损大幅收窄 管线开发及商业化取得重大进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770297","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621770297?lang=zh_cn&edition=full","pubTime":"2026-03-23 22:44","pubTimestamp":1774277065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布2025年业绩，其他收入及收益约2927.1万元，同比增长2.84倍;研究与开发成本为8162.4万元，同比减少13.86%;净亏损约1.05亿元，同比收窄43.29%。旗舰产品舒西利单抗，全球同类首创抗CD–22单抗—于2025年 7月在系统性红斑狼疮治疗的体外研究中取得突破性临床前结果，在小鼠模型中显示出减轻蛋白尿及潜在缓解狼疮性肾炎的前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618135630","title":"中国抗体-B(03681)附属终止租赁协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618135630?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:44","pubTimestamp":1773312249,"startTime":"0","endTime":"0","summary":"经考虑本公司优化资源配置及提升营运灵活性的策略，订约方已就提前终止租赁协议展开商讨。经长时间磋商后，订约方均同意终止租赁协议。董事会认为，终止协议对本公司向轻资产制造模式过渡而言属于合理且务实。董事会认为，终止协议不会对本集团的财务状况或营运构成任何重大不利影响，并符合本公司及其股东的整体利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","03681","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618053927","title":"中国抗体-B03月11日遭主力抛售57.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618053927","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618053927?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216937,"startTime":"0","endTime":"0","summary":"03月11日, 中国抗体-B股价跌1.55%，报收1.90元，成交金额259.8万元，换手率0.10%，振幅5.18%，量比0.41。中国抗体-B今日主力资金净流出57.0万元，上一交易日主力净流出121.4万元。该股近5个交易日下跌2.56%，主力资金累计净流入88.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入2221.2万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161802a6b78793&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161802a6b78793&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618687459","title":"中国抗体-B拟3月23日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618687459","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618687459?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:38","pubTimestamp":1773142693,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨中国抗体-B(03681.HK)公告，谨定于2026年3月23日(星期一)举行董事会会议，以考虑及通过集团截至2025年12月31日止年度全年业绩及其发布，以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310193825a6b55ef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310193825a6b55ef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125106901","title":"中国抗体-B（03681）2月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125106901","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125106901?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:36","pubTimestamp":1772699782,"startTime":"0","endTime":"0","summary":"中国抗体制药有限公司于2026年3月5日发布了截至2026年2月28日的股份变动月报。公告显示，公司香港联交所股票代码为03681，目前已发行普通股总数为1,386,638,336股，与上月底持平，报告期内未有新增发行、购回或库藏股变动。\n报告称，公司现行的股份期权计划截至报告期末仍有69,009,462份期权未行使，数量与上月底保持一致。本月内并无期权行使或失效行为，亦未出现新增发行或从库藏股份转让的情况。\n截至本月末，公司股本保持稳定，亦确认符合香港联交所的相关上市规则及法律法规要求。本次公告由执行董事、主席兼首席执行官梁瑞安签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617265045","title":"中国抗体-B03月05日主力净流入249.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2617265045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617265045?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:16","pubTimestamp":1772698565,"startTime":"0","endTime":"0","summary":"03月05日, 中国抗体-B股价涨1.54%，报收1.98元，成交金额929.9万元，换手率0.33%，振幅7.18%，量比0.59。中国抗体-B今日主力资金净流入249.0万元，上一交易日主力净流出47.1万元。该股近5个交易日下跌7.04%，主力资金累计净流出96.0万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入2914.5万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162140a44eea3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162140a44eea3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617052650","title":"中国抗体-B盘中异动 早盘急速拉升5.13%报2.050港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617052650","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617052650?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:17","pubTimestamp":1772677031,"startTime":"0","endTime":"0","summary":"2026年03月05日早盘10时17分，中国抗体-B股票出现异动，股价大幅上涨5.13%。截至发稿，该股报2.050港元/股，成交量300.27万股，换手率0.22%，振幅3.08%。资金方面，该股资金流入442.203万港元，流出157.545万港元。中国抗体-B股票所在的生物技术行业中，整体涨幅为2.57%。中国抗体-B公司简介：中国抗体制药有限公司是一家主要研究、发展、制造及商业化免疫性疾病疗法的中国香港生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603051017119543119f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603051017119543119f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","03681","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614852880","title":"中国抗体-B02月27日遭主力抛售231.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614852880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614852880?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:16","pubTimestamp":1772180162,"startTime":"0","endTime":"0","summary":"02月27日, 中国抗体-B股价跌5.16%，报收2.02元，成交金额1458.0万元，换手率0.51%，振幅6.57%，量比0.99。中国抗体-B今日主力资金净流出231.5万元，上一交易日主力净流出32.7万元。该股近5个交易日上涨1.00%，主力资金累计净流出179.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2653.4万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227162132a4cf0004&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227162132a4cf0004&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","03681","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614189017","title":"中国抗体-BSM17新适应症获批临床，研发加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2614189017","media":"国元证券(香港)","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614189017?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:14","pubTimestamp":1772093694,"startTime":"0","endTime":"0","summary":"针对炎症性肠病，公司计划利用已有I期数据快速推进至II期临床。根据预测，到2032年，AD药物市场规模将达352亿美元，而IBD患者人数超过680万，现有药物缓解率仅10%-20%，存在重大未满足需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614277992","title":"港股异动 | 中国抗体-B(03681)午前涨超5% 预计最早于二季度启动针对SM17 AD的II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2614277992","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614277992?lang=zh_cn&edition=full","pubTime":"2026-02-25 11:49","pubTimestamp":1771991346,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国抗体-B午前涨超5%，截至发稿，涨4.48%，报2.1港元，成交额952.99万港元。消息面上，中国抗体-B发布公告，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。有关研究数据将用作支持IBD适应症的进展直接推进II期临床开发。公司预计最早于本年第二季度启动针对AD的II期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4132","BK1574","BK1161","BK4588","03681","AD","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613717630","title":"中国抗体-B(03681)：SM17用于治疗IBD的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613717630?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:01","pubTimestamp":1771941713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。该机制使SM17成为UC有前景的治疗候选药物，其中已证实IL-25发挥促炎作用。公司进一步认为，靶向2型炎性通路上游调控因子的治疗策略可支持SM17成为用于治疗AD及IBD的具差异化、安全性更佳且有效的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1161","IBD","IND","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612250475","title":"中国抗体-B02月20日获主力加仓57.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612250475","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612250475?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:15","pubTimestamp":1771575326,"startTime":"0","endTime":"0","summary":"02月20日, 中国抗体-B股价涨2.56%，报收2.00元，成交金额1634.6万元，换手率0.58%，振幅5.64%，量比1.13。中国抗体-B今日主力资金净流入57.2万元，连续4日净流入，上一交易日主力净流入977.7万元。该股近5个交易日上涨18.34%，主力资金累计净流入1766.9万元；近20日主力资金累计净流入2756.6万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220161622a4b5db49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220161622a4b5db49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612252540","title":"港股异动 | 中国抗体-B(03681)再涨超5% SM17临床前研究凸显治疗CRSwNP和IPF强大潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2612252540","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612252540?lang=zh_cn&edition=full","pubTime":"2026-02-20 15:14","pubTimestamp":1771571647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国抗体-B再涨超5%，截至发稿，涨4.62%，报2.04港元，成交额1336.18万港元。消息面上，中国抗体宣布，其同类首创抗IL-17RB抗体SM17的临床前研究已在《欧洲呼吸杂志子刊-开放研究》上发表。中国抗体董事长、执行董事兼首席执行官梁瑞安称，非常高兴公司在《欧洲呼吸杂志子刊-开放研究》上发表了关于SM17的临床前研究，突显了其治疗CRSwNP和IPF的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","VXUS","03681","BK4588","BK1161","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611918552","title":"中国抗体-B盘中异动 急速上涨5.03%报1.880港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611918552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611918552?lang=zh_cn&edition=full","pubTime":"2026-02-13 10:11","pubTimestamp":1770948699,"startTime":"0","endTime":"0","summary":"2026年02月13日早盘10时11分，中国抗体-B股票出现异动，股价快速拉升5.03%。截至发稿，该股报1.880港元/股，成交量368.19万股，换手率0.27%，振幅6.15%。资金方面，该股资金流入647.98万港元，流出17.8515万港元。中国抗体-B股票所在的生物技术行业中，整体跌幅为1.13%。其相关个股中，中国抗体-B、科笛-B、维升药业-B涨幅较大，振幅较大的相关个股有北海康成-B、荃信生物-B、中国抗体-B，振幅分别为9.76%、7.37%、6.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021310113997a60562&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021310113997a60562&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","03681"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinomab.com","stockEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0928},{"period":"3month","weight":0.2662},{"period":"6month","weight":-0.0588},{"period":"1year","weight":0.408},{"period":"ytd","weight":0.3134}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国抗体制药有限公司是一家主要研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司。该公司主要研制以单克隆抗体为基础的生物制剂和新化学实体, 主要产品包括治疗类风湿关节炎的潜在单抗药物SM03。 该公司研发药物还包括有治疗特应性皮炎，哮喘，特发性肺纤维化及其他免疫性疾病潜力的SM17以及针对系统性红斑狼疮, 天疱疮，多发性硬化症及视神经脊髓炎普系疾病的SN1011 。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.001496},{"month":2,"riseRate":0.428571,"avgChangeRate":0.047286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.044577},{"month":4,"riseRate":0.857143,"avgChangeRate":0.070849},{"month":5,"riseRate":0.166667,"avgChangeRate":0.000649},{"month":6,"riseRate":0.333333,"avgChangeRate":0.050967},{"month":7,"riseRate":0.333333,"avgChangeRate":0.028393},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.139986},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048263},{"month":10,"riseRate":0,"avgChangeRate":-0.071195},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.003752},{"month":12,"riseRate":0.428571,"avgChangeRate":0.081979}],"exchange":"SEHK","name":"中国抗体-B","nameEN":"SINOMAB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国抗体-B(03681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国抗体-B,03681,中国抗体-B股票,中国抗体-B股票老虎,中国抗体-B股票老虎国际,中国抗体-B行情,中国抗体-B股票行情,中国抗体-B股价,中国抗体-B股市,中国抗体-B股票价格,中国抗体-B股票交易,中国抗体-B股票购买,中国抗体-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国抗体-B(03681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}